Mirvaso (Brimonidine Tartrate) Patent Expiration, LOE Window & CMS Spending

Mirvaso (Brimonidine Tartrate) by Galderma Laboratories: FDA Orange Book LOE 2031-06-13, 1 AB generics, $395K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGalderma Laboratories
FDA Application & PathwayN204708 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-06-13
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$395K
2024 Medicare Part D Spend$395K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel